Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chemoresistance remains a significant challenge in breast cancer treatment.
• Collagens and discoidin domain receptor 2 (DDR2), a collagen-activated receptor tyrosine kinase (RTK), are altered in tumors post-chemotherapy.
• The specific role of DDR2 in breast cancer chemoresistance, particularly its interaction with collagen, requires further elucidation.

Purpose of the Study:

• To investigate the association between DDR2, collagen type I, and chemoresistance in breast cancer.
• To determine the functional role of DDR2 in breast cancer cell proliferation and response to chemotherapy.
• To evaluate DDR2 as a potential prognostic factor in breast cancer.

Main Methods:

• Immunohistochemical analysis of DDR2 and collagen type I in 224 breast cancer tissue samples.
• In vitro studies utilizing chemosensitive and chemoresistant breast cancer cell lines.
• Assessment of DDR2's impact on cell proliferation and viability following epirubicin treatment.

Main Results:

• DDR2 immunoreactivity correlated positively with aggressive breast cancer phenotypes.
• DDR2 expression was linked to an increased risk of recurrence, particularly in patients undergoing chemotherapy.
• In vitro, DDR2 enhanced breast cancer cell proliferation and maintained cell viability post-epirubicin treatment in a collagen I-dependent manner.

Conclusions:

• DDR2 is implicated as a poor prognostic factor in human breast cancer.
• DDR2 contributes to tumor cell proliferation and resistance to chemotherapy.
• Targeting DDR2 may offer a therapeutic strategy to overcome chemoresistance in breast cancer.